443 related articles for article (PubMed ID: 20172276)
1. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
[TBL] [Abstract][Full Text] [Related]
2. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
Lauro A; Amaduzzi A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Grazi GL; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Siniscalchi A; Faenza S; D'Errico A; Di Simone M; Pironi L; Pinna AD
Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428
[TBL] [Abstract][Full Text] [Related]
3. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
Garcia M; Weppler D; Mittal N; Nishida S; Kato T; Tzakis A; Ruiz P
Transplant Proc; 2004 Mar; 36(2):323-4. PubMed ID: 15050146
[TBL] [Abstract][Full Text] [Related]
4. Intestinal and multivisceral transplantation immunosuppression protocols--literature review.
Trevizol AP; David AI; Dias ER; Mantovani D; Pécora R; D'Albuquerque LA
Transplant Proc; 2012 Oct; 44(8):2445-8. PubMed ID: 23026616
[TBL] [Abstract][Full Text] [Related]
5. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation.
Tzakis AG; Kato T; Nishida S; Levi DM; Madariaga JR; Nery JR; Mittal N; Regev A; Cantwell P; Gyamfi A; Weppler D; Miller J; Tryphonopoulos P; Ruiz P
Transplantation; 2003 Apr; 75(8):1227-31. PubMed ID: 12717207
[TBL] [Abstract][Full Text] [Related]
6. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation.
Tzakis AG; Kato T; Nishida S; Levi DM; Tryphonopoulos P; Madariaga JR; De Faria W; Nery JR; Regev A; Vianna R; Miller J; Esquenazi V; Weppler D; Ruiz P
Transplantation; 2003 May; 75(9):1512-7. PubMed ID: 12792506
[TBL] [Abstract][Full Text] [Related]
8. Twenty-seven consecutive intestinal and multivisceral transplants in adult patients: a 4-year clinical experience.
Lauro A; Di Benedetto F; Masetti M; Cautero N; Ercolani G; Vivarelli M; De Ruvo N; Cescon M; Varotti G; Dazzi A; Siniscalchi A; Begliomini B; Pironi L; Di Simone M; D'Errico A; Ramacciato G; Grazi G; Pinna AD
Transplant Proc; 2005; 37(6):2679-81. PubMed ID: 16182782
[TBL] [Abstract][Full Text] [Related]
9. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China.
Yuan-Xin L; Ning L; You-Sheng L; Xiao-Dong N; Ming L; Jian W; Jie-Shou L
Transplant Proc; 2010; 42(1):29-34. PubMed ID: 20172275
[TBL] [Abstract][Full Text] [Related]
10. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
[TBL] [Abstract][Full Text] [Related]
11. Results of intestinal and multivisceral transplantation in adult patients: Italian experience.
Lauro A; Dazzi A; Ercolani G; Cescon M; D'Errico A; Di Simone M; Grazi GL; Vivarelli M; Varotti G; De Ruvo N; Masetti M; Cautero N; Di Benedetto F; Siniscalchi A; Begliomini B; Lazzarotto T; Faenza S; Pironi L; Pinna AD
Transplant Proc; 2006; 38(6):1696-8. PubMed ID: 16908252
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab induction in deceased donor kidney transplantation.
Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
[TBL] [Abstract][Full Text] [Related]
15. Five-year outcomes with alemtuzumab induction after lung transplantation.
Shyu S; Dew MA; Pilewski JM; DeVito Dabbs AJ; Zaldonis DB; Studer SM; Crespo MM; Toyoda Y; Bermudez CA; McCurry KR
J Heart Lung Transplant; 2011 Jul; 30(7):743-54. PubMed ID: 21420318
[TBL] [Abstract][Full Text] [Related]
16. Impact of induction therapy on bacterial infections and long-term outcome in adult intestinal and multivisceral transplantation: a comparison of two different induction protocols: daclizumab vs. alemtuzumab.
Kimura T; Lauro A; Cescon M; Zanfi C; Dazzi A; Ercolani G; Grazi GL; Vivarelli M; Ravaioli M; Del Gaudio M; Cucchetti A; Zanello M; LaBarba G; Pironi L; Lazzarotto T; Pinna AD
Clin Transplant; 2009; 23(3):420-5. PubMed ID: 19537304
[TBL] [Abstract][Full Text] [Related]
17. Intestinal transplantation with alemtuzumab (Campath-1H) induction for adult patients.
Nishida S; Levi DM; Moon JI; Madariaga JR; Kato T; Selvaggi G; Tryphonopoulos P; DeFaria W; Santiago S; Gaynor J; Weppler D; Martinez E; Ruiz P; Tzakis AG
Transplant Proc; 2006; 38(6):1747-9. PubMed ID: 16908270
[TBL] [Abstract][Full Text] [Related]
18. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
[TBL] [Abstract][Full Text] [Related]
19. Campath induction for kidney transplantation: report of 297 cases.
Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
[TBL] [Abstract][Full Text] [Related]
20. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks.
Abu-Elmagd KM; Mazariegos G; Costa G; Soltys K; Bond G; Sindhi R; Green M; Jaffe R; Wu T; Koritsky D; Matarese L; Schuster B; Martin L; Dvorchik I; Nalesnik MA
Transplantation; 2009 Oct; 88(7):926-34. PubMed ID: 19935465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
